Apoptosis modulated by oxidative stress and inflammation during obstructive nephropathy

Inflammation and Allergy - Drug Targets

Volumn 11, Issue 4, 2012, Pages 303-312

  Manucha, Walter ^a,b   Vallés, Patricia G ^a,b  

^a FACULTAD DE CIENCIAS MÉDICAS   (Argentina)

^b IMBECU CONICET (National Council of Scientific and Technical Research of Argentina)   (Argentina)

Author keywords

Angiotensin II; apoptosis; mitochondria; obstructive nephropathy; oxidative stress

Indexed keywords

ANGIOTENSIN II; ANGIOTENSIN RECEPTOR; CAVEOLIN 1; CELL ADHESION MOLECULE; CHEMOKINE; CYCLOOXYGENASE 2; CYTOKINE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; GROWTH FACTOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERCELLULAR ADHESION MOLECULE 1; LOSARTAN; OSTEOGENIC PROTEIN 1; OSTEOPONTIN; PARICALCITOL; PARTHENOLIDE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR; PYRROLIDINE DITHIOCARBAMATE; REACTIVE OXYGEN METABOLITE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE; ROSUVASTATIN; SALAZOSULFAPYRIDINE; SERINE PROTEINASE OMI; SIMVASTATIN; SIRTUIN 1; TRANDOLAPRIL; TRANSFORMING GROWTH FACTOR BETA1; UNINDEXED DRUG;

APOPTOSIS; ATROPHY; CELL INFILTRATION; CHRONIC KIDNEY DISEASE; GENE EXPRESSION; HUMAN; INFLAMMATION; KIDNEY DISEASE; KIDNEY FIBROSIS; MACROPHAGE; MITOCHONDRION; NONHUMAN; OBSTRUCTIVE NEPHROPATHY; ONCOGENE RAS; OXIDATIVE STRESS; RECEPTOR DOWN REGULATION; REVIEW; SIGNAL TRANSDUCTION; URETER OBSTRUCTION;

ANIMALS; APOPTOSIS; FIBROSIS; HUMANS; INFLAMMATION; KIDNEY DISEASES; OXIDATIVE STRESS;

EID: 84868606565     PISSN: 18715281     EISSN: None     Source Type: Journal    
DOI: 10.2174/187152812800958997     Document Type: Review

References (132)

1. Becker, A.; Baum, M. Obstructive uropathy. Early Hum. Dev., 2006, 82, 15-22.
2. Ahmadzadeh, A.; Tahmasebi, M.; Gharibvand, M.M. Causes and outcome of prenatally diagnosed hydronephrosis. Saudi. J. Kidney Dis. Transpl., 2009, 20, 246-50.
3. Cachat, F.; Lange-Sperandio, B.; Chang, A.Y.; Kiley, S.C.; Thornhill, B.A.; Forbes, M.S.; Chevalier, R.L. Ureteral obstruction in neonatal mice elicits segment-specific tubular cell responses leading to nephron loss. Kidney Int., 2003, 63(2), 564-75.
4. Smith, J.M.; Stablein, D.M.; Munoz, R.; Hebert, D.; McDonald, R.A. Contributions of the Transplant Registry: The 2006 Annual Report of the North American Pediatric Renal Trials and Collaborative Studies (NAPRTCS). Pediatr. Transplant, 2007, 11, 366-373.
5. Klahr, S.; Morrissey, J. Obstructive nephropathy and renal fibrosis. Am. J. Physiol. Renal Physiol, 2002, 283, F861-F875.
6. Manucha, W. Biochemical-molecular markers in unilateral ureteral obstruction. Biocell, 2007, 31(1), 1-12.
7. Dendooven, A.; Ishola, D.A. Jr; Nguyen, T.Q.; Van der Giezen, D.M.; Kok, R.J.; Goldschmeding, R.; Joles, J.A. Oxidative stress in obstructive nephropathy. Int. J. Exp. Pathol., 2011, 92(3), 202-10.
8. Filiopoulos, V.; Vlassopoulos, D. Inflammatory syndrome in chronic kidney disease: pathogenesis and influence on outcomes. Inflamm. Allergy Drug Targets, 2009, 8(5), 369-82.
9. Chevalier, R.L.; Forbes, M.S.; Thornhill, B.A. Ureteral obstruction as a model of renal interstitial fibrosis and obstructive nephropathy. Kidney Int., 2009, 75 (11), 1145-52.
10. Ricardo, S.D.; Levinson, M.E.; DeJoseph, M.R.; Diamond, J.R. Expression of adhesion molecules in rat renal cortex during experimental hydronephrosis. Kidney int., 1996, 50(6), 2002-10.
11. Higgins, D.F.; Kimura, K.; Bernhardt, W.M.; Shrimanker, N.; Akai, Y.; Hohenstein, B.; Saito, Y.; Johnson, R.S.; Kretzler, M.; Cohen, C.D.; Eckardt, K.U.; Iwano, M.; Haase, V.H. Hypoxia promotes fibrogenesis in vivo via HIF-1 stimulation of epithelial-to-mesenchymal transition. J. Clin. Invest., 2007, 117(12), 3810-20.
12. Crisman, J.M.; Richards, L.L.; Valach, D.P.; Franzoni, D.F.; Diamond, J.R. Chemokine expression in the obstructed kidney. Exp. Nephrol., 2001, 9(4), 241-8.
13. Schreiner, G.F.; Harris, K.P.; Purkerson, M.L.; Klahr, S. Immunological aspects of acute ureteral obstruction: immune cell infiltrate in the kidney. Kidney Int., 1988, 34(4), 487-93.
14. Diamond, J.R.; Kees-Folts, D.; Ding, G.; Frye, J.E.; Restrepo, N.C. Macrophages, monocyte chemoattractant peptide-1, and TGF-beta 1 in experimental hydronephrosis. Am. J. Physiol., 1994, 266(6 Pt 2), F926-33.
15. Shanmugam, M.K.; Bhatia, M. The role of pro-inflammatory molecules and pharmacological agents in acute pancreatitis and sepsis. Inflamm. Allergy Drug Targets, 2010, 9(1), 20-31.
16. Grande, M.T.; Pérez-Barriocanal, F.; López-Novoa, J.M. Role of inflammation in túbulo-interstitial damage associated to obstructive nephropathy. J. Inflamm. (Lond), 2010, 22, 7-19.
17. Pimentel, J.L. Jr.; Montero, A.; Wang, S.; Yosipiv, I.; el-Dahr, S.; Martínez-Maldonado, M. Sequential changes in renal expression of renin-angiotensin system genes in acute unilateral ureteral obstruction. Kidney Int., 1995, 48(4), 1247-53.
18. Klahr, S. Urinary tract obstruction. Semin. Nephrol., 2011, 21(2), 133-45.
19. Sachse, A., Wolf G. Angiotensin II-induced reactive oxygen species and the kidney. J. Am. Soc. Nephrol., 2007, 18(9), 2439-46.
20. Pedzik, A.; Paradowski, M.; Rysz, J. Oxidative stress in nephrology. Pol. Merkur. Lekarski., 2010, 28(163), 56-60.
21. Franklin, R.A.; Rodriguez-Mora, O.G.; Lahair, M.M.; McCubrey, J.A. Activation of the calcium/calmodulin-dependent protein kinases as a consequence of oxidative stress. Antioxid Redox Signal, 2006, 8(9-10), 1807-17.
22. Manucha, W.; Kurbán, F.; Mazzei, L.; Benardón, M.E.; Bocanegra, V.; Tosi, M.R.; Vallés, P. eNOS/Hsp70 interaction on rosuvastatin cytoprotective effect in neonatal obstructive nephropathy. Eur. J. Pharmacol., 2011, 650(2-3), 487-95.
23. Lodha, S.; Dani, D.; Mehta, R.; Bhaskaran, M.; Reddy, K.; Ding, G.; Singhal, P.C. Angiotensin II-induced mesangial cell apoptosis: role of oxidative stress. Mol. Med., 2002, 8(12), 830-40.
24. Cooper, M.E.; Tikellis, C.; Thomas, M.C. Preventing diabetes in patients with hypertension: one more reason to block the renin- angiotensin system. J. Hypertens. Suppl., 2006, 24(1), S57-63.
25. Negro, R. Endothelial effects of antihypertensive treatment: focus on irbesartan. Vasc. Health Risk Manag., 2008, 4(1), 89-101.
26. Ricardo, S.D.; Franzoni, D.F.; Roesener, C.D.; Crisman, J.M.; Diamond, J.R. Angiotensinogen and AT1 antisense inhibition of osteopontin translation in rat proximal tubular cells. Am. J. Physiol. Renal Physiol., 2000, 278(5), F708-16.
27. Eddy, A.A.; Giachelli, C.M. Renal expression of genes that promote interstitial inflammation and fibrosis in rats with protein-overload proteinuria. Kidney Int., 1995, 47, 1546-1557.
28. Kleinman, J.G.; Worcester, E.M.; Beshensky, A.M.; Sheridan, A.M.; Bonventre, J.V.; Brown, D. Upregulation of osteopontin expression by ischemia in rat kidney. Ann. NY Acad Sci., 1995, 760, 321-323.
29. Cao, Z.; Cooper, M.E. Role of angiotensin II in tubulointerstitial injury. Semin. Nephrol., 2001, 21(6), 554-62.
30. Diamond, J.R.; Ricardo, S.D.; Klahr, S. Mechanisms of interstitial fibrosis in obstructive nephropathy. Semin. Nephrol., 1998, 18(6), 594-602.
31. Couser, W.G.; Johnson, R.J. Mechanisms of progressive renal disease in glomerulonephritis. Am. J. Kidney Dis, 1994, 23(2), 193-8.
32. Carlström, M. Causal link between neonatal hydronephrosis and later development of hypertension. Clin. Exp. Pharmacol. Physiol, 2010, 37(2), e14-23.
33. Shi, Y.; Pedersen, M.; Li, C.; Wen, J.G.; Thomsen, K.; Stødkilde-Jørgensen, H.; Jørgensen, T.M.; Knepper, M.A.; Nielsen, S.; Djurhuus, J.C.; Frøkiaer, J. Early release of neonatal ureteral obstruction preserves renal function. Am. J. Physiol. Renal Physiol., 2004, 286(6), F1087-99.
34. Ramonas, H.; Zelvys, A. Treatment of patients with urinary tract obstruction and significant renal impairment. Medicina (Kaunas), 2002, 38 (Suppl 1), 30-5.
35. Imai, E.; Takabatake, Y.; Mizui, M.; Isaka, Y. Gene therapy in renal diseases. Kidney Int, 2004, 65(5), 1551-5.
36. Manrique, C.; Lastra, G.; Gardner, M.; Sowers, J.R. The renin angiotensin aldosterone system in hypertension: roles of insulin resistance and oxidative stress. Med. Clin. North Am., 2009, 93(3), 569-82.
37. Ghittoni, R.; Lazzerini, P.E.; Pasini, F.L.; Baldari, C.T. T lymphocytes as targets of statins: molecular mechanisms and therapeutic perspectives. Inflamm. Allergy Drug Targets, 2007, 6(1), 3-16.
38. Li, M.; Batuman, V. Vitamin D: a new hope for chronic kidney disease? Kidney Int., 2009, 76(12), 1219-21.
39. Kostapanos, M.S.; Liberopoulos, E.N.; Elisaf, M.S. Statin pleiotropy against renal injury. J. Cardiometab. Syndr., 2009, 4(1), E4-9.
40. Manucha, W.; Vallés, P.G. Cytoprotective role of nitric oxide associated with Hsp70 expression in neonatal obstructive nephropathy. Nitric Oxide, 2008, 18(3), 204-15.
41. Morisada, N.; Nomura, M.; Nishii, H.; Furuno, Y.; Sakanashi, M.; Sabanai, K.; Toyohira, Y.; Ueno, S.; Watanabe, S.; Tamura, M.; Matsumoto, T.; Tanimoto, A.; Sasaguri, Y.; Shimokawa, H.; Kusuhara, K.; Yanagihara, N.; Shirahata, A.; Tsutsui, M. Complete disruption of all nitric oxide synthase genes causes markedly accelerated renal lesion formation following unilateral ureteral obstruction in mice in vivo. J. Pharmacol. Sci., 2010,114(4), 379-89.
42. Yoo, K.H.; Thornhill, B.A.; Forbes, M.S.; Chevalier, R.L. Inducible nitric oxide synthase modulates hydronephrosis following partial or complete unilateral ureteral obstruction in the neonatal mouse. Am. J. Physiol. Renal Physiol., 2010, 298(1), F62-71.
43. Eddy, A.A. Progression in chronic kidney disease. Adv. Chronic Kidney Dis., 2005, 12(4), 353-65.
44. Mazzei, L.; García, I.M.; Cacciamani, V.; Benardón, M.E.; Manucha, W. WT-1 mRNA expression is modulated by nitric oxide availability and Hsp70 interaction after neonatal unilateral ureteral obstruction. Biocell, 2010, 34(3), 121-32.
45. Ekblom, P. Developmentally regulated conversion of mesenchime to epithelium. FASEB, 1989, 3, 2141-2160.
46. Liapis, H. Biology of congenital obstructive nephropathy. Nephron Exp. Nephrol., 2003, 93, 87-91.
47. Power, R.E.; Doyle, B.T.; Higgins, D.; Brady, H.R.; Fitzpatrick, J.M.; Watson, R.W. Mechanical deformation induced apoptosis in human proximal renal tubular epithelial cells is caspase dependent. J. Urol., 2004, 171, 457-61.
48. Mazzei, L.J.; García, I.M.; Altamirano, L.; Docherty, N.G.; Manucha, W. Rosuvastatin preserves renal structure following unilateral ureteric obstruction in the neonatal rat. Am. J. Nephrol., 2012, 35 (2), 103-113.
49. Forrester, J.S.; Libby, P. The inflammation hypothesis and its potential relevance to statin therapy. Am. J. Cardiol., 2007, 99(5), 732-8.
50. Pritchard-Jones, K.; Fleming, S.; Davidson, D.; Bickmore, W.; Porteous, D.; Gosden, C.; Bard, J.; Buckler, A.; Pelletier, J.; Housman, D.; van Heyningen, V.; Hastie, N. The candidate Wilms' tumour gene is involved in genitourinary development. Nature, 1990, 346(6280), 194-7.
51. Hosono, S.; Gross, I.; English, M.A.; Hajra, K.M.; Fearon, E.R.; Licht, J.D. E-cadherin is a WT1 target gene. J. Biol. Chem., 2000, 275(15), 10943-53.
52. Manson, S.R.; Niederhoff, R.A.; Hruska, K.A.; Austin, P.F. The BMP-7-Smad1/5/8 pathway promotes kidney repair after obstruction induced renal injury. J Urol, 2011, 185(6 Suppl), 2523-30.
53. Huang, B.; Pi, L.; Chen, C.; Yuan, F.; Zhou, Q.; Teng, J.; Jiang, T. WT1 and Pax2 Re-Expression Is Required for Epithelial-Mesenchymal Transition in 5/6 Nephrectomized Rats and Cultured Kidney Tubular Epithelial Cells. Cells Tissues Organs, 2012, 195(4), 296-312.
54. Falahatpisheh, M.H.; Nanez, A.; Ramos, K.S. AHR Regulates WT1 Genetic Programming During Murine Nephrogenesis. Mol. Med., 2011, 17(11-12), 1275-84.
55. Ristola, M.; Arpiainen, S.; Saleem, M.A.; Holthöfer, H.; Lehtonen, S. Transcription of nephrin-Neph3 gene pair is synergistically activated by WT1 and NF-{kappa}B and silenced by DNA methylation. Nephrol Dial Transplant, 2011, Oct 6. doi: 10.1093/ndt/gfr576
56. Tian, S.; Ding, G.; Jia, R.; Chu, G. Tubulointerstitial macrophage accumulation is regulated by sequentially expressed osteopontin and macrophage colony-stimulating factor: implication for the role of atorvastatin. Mediators Inflamm., 2006, 2006(2), 12919.
57. Panzer, U.; Thaiss, F.; Zahner, G.; Barth, P.; Reszka, M.; Reinking, R.R.; Wolf, G.; Helmchen, U.; Stahl, R.A. Monocyte chemoattractant protein-1 and osteopontin differentially regulate monocytes recruitment in experimental glomerulonephritis. Kidney Int., 2001, 59(5), 1762-1769.
58. Isbel, N.M.; Hill, P.A.; Foti, R.; Mu, W.; Hurst, L.A.; Stambe, C.; Lan, H.Y.; Atkins, R.C.; Nikolic-Paterson, D.J. Tubules are the major site of M-CSF production in experimental kidney disease: correlation with local macrophage proliferation. Kidney Int., 2001, 60(2), 614-625.
59. Isbel, N.M.; Nikolic-Paterson, D.J.; Hill, P.A.; Dowling, J.; Atkins, R.C. Local macrophage proliferation correlates with increased renal M-CSF expression in human glomerulonephritis. Nephrology Dialysis Transplantation, 2001, 16(8), 1638-1647.
60. Vieira, J.M. Jr.; Mantovani, E.; Rodrigues, L.T.; Dellê, H.; Noronha, I.L.; Fujihara, C.K.; Zatz, R. Simvastatin attenuates renal inflammation, tubular transdifferentiation and interstitial fibrosis in rats with unilateral ureteral obstruction. Nephrol. Dial. Transplant, 2005, 20(8), 1582-91.
61. Kirmizis, D.; Papagianni, A.; Dogrammatzi, F.; Skoura, L.; Belechri, A.M.; Alexopoulos, E.; Efstratiadis, G.; Memmos, D. Effects of simvastatin on markers of inflammation, oxidative stress and endothelial cell apoptosis in patients on chronic hemodialysis. J. Atheroscler. Thromb., 2010, 17(12), 1256-65.
62. Mizuguchi, Y.; Miyajima, A.; Kosaka, T.; Asano, T.; Asano, T.; Hayakawa, M. Atorvastatin ameliorates renal tissue damage in unilateral ureteral obstruction. J. Urol., 2004, 172(6 Pt 1), 2456-9.
63. Meng, X.M.; Ru, H.X.; Xiao, J.; Chen, H.Y.; Zhong, X.; Chung, A.C.; Yao, L.H. Diverse roles of TGF- receptor II in renal fibrosis and inflammation in vivo and in vitro. J. Pathol., 2011, doi: 10.1002/path.3976.
64. Sparrow, C.P.; Burton, C.A.; Hernandez, M.; Mundt, S.; Hassing, H.; Patel, S.; Rosa, R.; Hermanowski-Vosatka, A.; Wang, P.R.; Zhang, D.; Peterson, L.; Detmers, P.A.; Chao, Y.S.; Wright, S.D. Simvastatin has anti-inflammatory and antiatherosclerotic activities independent of plasma cholesterol lowering. Arterioscler. Thromb. Vasc. Biol., 2001, 21, 115-121.
65. Terada, Y.; Inoshita, S.; Nakashima, O.; Yamada, T.; Kuwahara, M.; Sasaki, S.; Marumo, F. Lovastatin inhibits mesangial cell proliferation via p27Kip1. J. Am. Soc. Nephrol., 1998, 9, 2235-2243.
66. Dichtl, W.; Dulak, J.; Frick, M.; Alber, H.F.; Schwarzacher, S.P.; Ares, M.P.; Nilsson, J.; Pachinger, O.; Weidinger, F. HMG-CoA reductase inhibitors regulate inflammatory transcription factors in human endothelial and vascular smooth muscle cells. Arterioscler. Thromb. Vasc. Biol., 2003, 23, 58-63.
67. Ichikawa, I.; Brenner, B.M. Local intrarenal vasoconstrictor-vasodilator interactions in mild partial ureteral obstruction. Am. J. Physiol., 1979, 236(2), F131-40.
68. Klahr, S.; Morrissey, J.J. The role of growth factors, cytokines, and vasoactive compounds in obstructive nephropathy. Semin. Nephrol., 1998, 18(6), 622-32.
69. Touyz, R.M.; Schiffrin, E.L. Signal transduction mechanisms mediating the physiological and pathophysiological actions of angiotensin II in vascular smooth muscle cells. Pharmacol. Rev., 2000, 52, 639-672.
70. Ruiz-Ortega, M.; Esteban, V.; Suzuki, Y.; Ruperez, M.; Mezzano, S.; Ardiles, L.; Justo, P.; Ortiz, A.; Egido, J. Renal expression of angiotensin type 2 (AT2) receptors during kidney damage. Kidney Int., 2003, 64, S21-S26.
71. Ruiz-Ortega, M.; Rupérez, M.; Esteban, V.; Rodriguez-Vita, J.; Sanchez-López, E.; Egido, J. Modulation of angiotensin II effects, a potential novel approach to inflammatory and immune diseases. Curr. Med. Chem., 2003, 2, 379-394.
72. Akishita, M.; Horiuchi, M.; Yamada, H.; Zhang, L.; Shirakami, G.; Tamura, K.; Ouchi, Y.; Dzau, V.J. Inflammation influences vascular remodeling through AT2 receptor expression and signaling. Physiol. Genomics, 2000, 24, 13-20.
73. Guijarro, C.; Egido, J. Transcription factor B (NF- B) in renal disease. Kidney Int., 2001, 59, 415-424.
74. Ruiz-Ortega, M.; Bustos, C.; Hernández-Presa, M.A.; Lorenzo, O.; Plaza, J.J.; Egido, J. Angiotensin II participates in mononuclear cell recruitment in the kidney through nuclear factor-kappa B activation and monocyte chemoattractant protein-1 gene expression. J. Immunol., 1998, 161, 430-439.
75. Morrissey, J.J.; Klahr, S. Enalapril decreases nuclear factor B activation in the kidney with ureteral obstruction. Kidney Int., 1997, 52, 926-933.
76. Klahr, S.; Morrissey, J.J. The role of vasoactive compounds, growth factors and cytokines in the progression of renal disease. Kidney Int., 2000, 75, S7-S14.
77. Manucha, W.; Oliveros, L.; Carrizo, L.; Seltzer, A.; Vallés, P. Losartan modulation on NOS isoforms and COX-2 expression in early renal fibrogenesis in unilateral obstruction. Kidney Int., 2004, 65(6), 2091-107.
78. Manucha, W.; Carrizo, L.; Ruete, C.; Molina, H.; Vallés, P. Angiotensin II type I antagonist on oxidative stress and heat shock protein 70 (HSP 70) expression in obstructive nephropathy. Cell Mol. Biol. (Noisy-le-grand), 2005, 51(6), 547-55.
79. Williams, T.M.; Lisanti, M.P. The Caveolin genes: from cell biology to medicine. Ann. Med., 2004, 36(8), 584-95.
80. Bocanegra, V.; Manucha, W.; Peña, M.R.; Cacciamani, V.; Vallés, P.G. Caveolin-1 and Hsp70 interaction in microdissected proximal tubules from spontaneously hypertensive rats as an effect of Losartan. J. Hypertens., 2010, 28(1), 143-55.
81. Vallés, P.G.; Manucha, W.; Carrizo, L.; Vega Perugorria, J.; Seltzer, A.; Ruete, C. Renal caveolin-1 expression in children with unilateral ureteropelvic junction obstruction. Pediatr. Nephrol., 2007, 22(2), 237-48.
82. Li, H.; Nord, E.P. Functional caveolae are a prerequisite for CD40 signaling in human renal proximal tubule cells. Am. J. Physiol. Renal Physiol., 2004, 286(4), F711-9.
83. Yuan, K.; Huang, C.; Fox, J.; Gaid, M.; Weaver, A.; Li, G.; Singh, B.B.; Gao, H.; Wu, M. Elevated inflammatory response in caveolin-1- deficient mice with Pseudomonas aeruginosa infection is mediated by STAT3 protein and nuclear factor kappaB (NF-kappaB). J. Biol. Chem., 2011, 286(24), 21814-25.
84. Kim, J.M.; Heo, H.S.; Choi, Y.J.; Ye, B.H.; Mi, H.Y.; Seo, A.Y.; Yu, B.P.; Leeuwenburgh, C.; Chung, H.Y.; Carter, C.S. Inhibition of NF- B-induced inflammatory responses by angiotensin II antagonists in aged rat kidney. Exp. Gerontol., 2011, 46(7), 542-8.
85. Esteban, V.; Lorenzo, O.; Rupérez, M.; Suzuki, Y.; Mezzano, S.; Blanco, J.; Kretzler, M.; Sugaya, T.; Egido, J.; Ruiz-Ortega, M. Angiotensin II, via AT1 and AT2 receptors and NF-kappaB pathway, regulates the inflammatory response in unilateral ureteral obstruction. J. Am. Soc. Nephrol., 2004, 15(6), 1514-29.
86. Rohatgi, R.; Flores, D. Intratubular hydrodynamic forces influence tubulointerstitial fibrosis in the kidney. Curr. Opin. Nephrol. Hypertens., 2010,19(1), 65-71.
87. Gruden, G.; Setti, G.; Hayward, A.; Sugden, D.; Duggan, S.; Burt, D.; Buckingham, R.E.; Gnudi, L.; Viberti, G. Mechanical stretch induces monocyte chemoattractant activity via an NF-kappaB-dependent monocyte chemoattractant protein-1-mediated pathway in human mesangial cells: inhibition by rosiglitazone. J. Am. Soc. Nephrol., 2005, 16(3), 688-96.
88. Chok, M.K.; Ferlicot, S.; Conti, M.; Almolki, A.; Dürrbach, A.; Loric, S.; Benoît, G.; Droupy, S.; Eschwège, P. Renoprotective potency of heme oxygenase-1 induction in rat renal ischemia-reperfusion. Inflamm. Allergy Drug Targets, 2009, 8(4), 252-9.
89. Carlsen, I.; Donohue, K.E.; Jensen, A.M.; Selzer, A.L.; Chen, J.; Poppas, D.P.; Felsen, D.; Frøkiær, J.; Nørregaard, R. Increased cyclooxygenase-2 expression and prostaglandin E2 production in pressurized renal medullary interstitial cells. Am. J. Physiol. Regul. Integr. Comp. Physiol., 2010, 299(3), R823-31.
90. Holick, M.F. Vitamin D for health and in chronic kidney disease. Semin. Dial., 2005, 18, 266-275.
91. Querings, K.; Girndt, M.; Geisel, J.; Georg, T.; Tilgen, W.; Reichrath, J. 25-hydroxyvitamin D deficiency in renal transplant recipients. J. Clin. Endocrinol. Metab., 2006, 91, 526-529.
92. Gonzalez, E.A.; Sachdeva, A.; Oliver, D.A.; Martin, K.J. Vitamin D insufficiency and deficiency in chronic kidney disease. A single center observational study. Am. J. Nephrol., 2004, 24, 503-510.
93. Tan, X.; Li, Y.; Liu, Y. Paricalcitol attenuates renal interstitial fibrosis in obstructive nephropathy. J. Am. Soc. Nephrol., 2006, 17(12), 3382-93.
94. Tan, X.; Wen, X.; Liu, Y. Paricalcitol inhibits renal inflammation by promoting vitamin D receptor-mediated sequestration of NF-kappaB signaling. J. Am. Soc. Nephrol., 2008, 19(9), 1741-52.
95. Zhang, Y.; Kong, J.; Deb, D.K.; Chang, A.; Li, Y.C. Vitamin D receptor attenuates renal fibrosis by suppressing the renin-angiotensin system. J. Am. Soc. Nephrol., 2010, 21(6), 966-73.
96. Barreto, F.C.; de Oliveira, R.A.; Oliveira, R.B.; Jorgetti, V. Pharmacotherapy of chronic kidney disease and mineral bone disorder. Expert Opin. Pharmacother., 2011, 12(17), 2627-40.
97. Zittermann, A.; Tenderich, G.; Koerfer, R. Vitamin D and the adaptive immune system with special emphasis to allergic reactions and allograft rejection. Inflamm. Allergy Drug Targets, 2009, 8(2), 161-8.
98. Tan, X.; He, W.; Liu, Y. Combination therapy with paricalcitol and trandolapril reduces renal fibrosis in obstructive nephropathy. Kidney Int., 2009, 76(12), 1248-57.
99. García, I.M.; Altamirano, L.; Mazzei, L.J.; Fornés, M.W.; Molina, M.N.; Ferder, L.; Manucha, W. Role of mitochondria in paricalcitol- mediated cytoprotection during obstructive nephropathy. Am. J. Physiol. Renal Physiol., 2012, doi: 10.1152/ajprenal.00617. 2011.
100. Wang, X.X.; Jiang, T.; Shen, Y.; Santamaria, H.; Solis, N.; Arbeeny, C.; Levi, M. Vitamin D receptor agonist doxercalciferol modulates dietary fat-induced renal disease and renal lipid metabolism. Am. J. Physiol. Renal Physiol., 2011, 300(3), F801-10.
101. Husain, K.; Suarez, E.; Isidro, A.; Ferder, L. Effects of paricalcitol and enalapril on atherosclerotic injury in mouse aortas. Am. J. Nephrol., 2010, 32(4), 296-304.
102. Newmeyer, D.D.; Farschon, D.M.; Reed, J.C. Cell-free apoptosis in Xenopus egg extracts: inhibition by Bcl-2 and requirement for an organelle fraction enriched in mitochondria. Cell, 1994, 79, 353-364.
103. Granata, S.; Zaza, G.; Simone, S.; Villani, G.; Latorre, D.; Pontrelli, P.; Carella, M.; Schena, F.P.; Grandaliano, G.; Pertosa, G. Mitochondrial dysregulation and oxidative stress in patients with chronic kidney disease. BMC Genomics, 2009, 10, 388-400.
104. Benigni, A.; Corna, D.; Zoja, C.; Sonzogni, A.; Latini, R.; Salio, M.; Conti, S.; Rottoli, D.; Longaretti, L.; Cassis, P.; Morigi, M.; Coffman, T.M.; Remuzzi, G. Disruption of the Ang II type 1 receptor promotes longevity in mice. J. Clin. Invest., 2009, 119(3), 524-30.
105. de Cavanagh, E.M.; Inserra, F.; Ferder, L. Angiotensin II blockade: a strategy to slow ageing by protecting mitochondria? Cardiovasc. Res., 2011, 89(1), 31-40.
106. Navarrete-Reyes, A.P.; Montaña-Alvarez, M. Inflammaging: Aging inflammatory origin. Rev. Invest. Clin., 2009, 61(4), 327-36.
107. John, G.B.; Cheng, C.Y.; Kuro-o, M. Role of Klotho in aging, phosphate metabolism, and CKD. Am. J. Kidney Dis., 2011, 58(1), 127-34.
108. He, W.; Wang, Y.; Zhang, M.Z.; You, L.; Davis, L.S.; Fan, H.; Yang, H.C.; Fogo, A.B.; Zent, R.; Harris, R.C.; Breyer, M.D.; Hao, C.M. Sirt1 activation protects the mouse renal medulla from oxidative injury. J. Clin. Invest., 2010, 120(4), 1056-68.
109. Moreno, J.A.; Izquierdo, M.C.; Sanchez-Niño, M.D.; Suárez-Alvarez, B.; Lopez-Larrea, C.; Jakubowski, A.; Blanco, J.; Ramirez, R.; Selgas, R.; Ruiz-Ortega, M.; Egido, J.; Ortiz, A.; Sanz, A.B. The inflammatory cytokines TWEAK and TNF reduce renal klotho expression through NF B. J. Am. Soc. Nephrol., 2011, 22(7), 1315-25.
110. Demirbilek, S.; Emre, M.H.; Aydin, E.N.; Edali, M.N.; Aksoy, R.T.; Akin, M.; Gürünlüolu, K.; Tas, E.; Ay, S.; Yilmaz, Z. Sulfasalazine reduces inflammatory renal injury in unilateral ureteral obstruction. Pediatr. Nephrol., 2007, 22(6), 804-12.
111. Owada, S.; Maeba, T.; Sugano, Y.; Hirayama, A.; Ueda, A.; Nagase, S.; Goto, S.; Nishijima, F.; Bannai, K.; Yamato, H. Spherical carbon adsorbent (AST-120) protects deterioration of renal function in chronic kidney disease rats through inhibition of reactive oxygen species production from mitochondria and reduction of serum lipid peroxidation. Nephron Exp. Nephrol., 2010, 115(4), e101-11.
112. Møller, J.C.; Jørgensen, T.M.; Mortensen, J. Proximal tubular atrophy: qualitative and quantitative structural changes in chronic obstructive nephropathy in the pig. Cell Tissue Res., 1986, 244(3), 479-91.
113. de Cavanagh, E.M.; Ferder, L.; Toblli, J.E.; Piotrkowski, B.; Stella, I.; Fraga, C.G.; Inserra, F. Renal mitochondrial impairment is attenuated by AT1 blockade in experimental Type I diabetes. Am. J. Physiol. Heart Circ. Physiol., 2008, 294(1), H456-65.
114. de Cavanagh, E.M.; Ferder, L.F.; Ferder, M.D.; Stella, I.Y.; Toblli, J.E.; Inserra, F. Vascular structure and oxidative stress in salt-loaded spontaneously hypertensive rats: effects of losartan and atenolol. Am. J. Hypertens., 2010, 23(12), 1318-25.
115. de Cavanagh, E.M.; Toblli, J.E.; Ferder, L.; Piotrkowski, B.; Stella, I.; Inserra, F. Renal mitochondrial dysfunction in spontaneously hypertensive rats is attenuated by losartan but not by amlodipine. Am. J. Physiol. Regul. Integr. Comp. Physiol., 2006, 290(6), R1616-25.
116. de Cavanagh, E.M.; Toblli, J.E.; Ferder, L.; Piotrkowski, B.; Stella, I.; Fraga, C.G.; Inserra, F. Angiotensin II blockade improves mitochondrial function in spontaneously hypertensive rats. Cell Mol. Biol. (Noisy-le-grand), 2005, 51(6), 573-8.
117. Ferder, L.; Inserra, F.; Martínez-Maldonado, M. Inflammation and the metabolic syndrome: role of angiotensin II and oxidative stress. Curr. Hypertens Rep., 2006, 8(3), 191-8.
118. Mizuguchi, Y.; Chen, J.; Seshan, S.V.; Poppas, D.P.; Szeto, H.H.; Felsen, D. A novel cell-permeable antioxidant peptide decreases renal tubular apoptosis and damage in unilateral ureteral obstruction. Am. J. Physiol. Renal Physiol., 2008, 295(5), F1545-53.
119. Kim, J.; Kim, D.S.; Park, M.J.; Cho, H.J.; Zervos, A.S.; Bonventre, J.V.; Park, K.M. Omi/HtrA2 protease is associated with tubular cell apoptosis and fibrosis induced by unilateral ureteral obstruction. Am. J. Physiol. Renal Physiol., 2010, 298(6), F1332-40.
120. Manucha, W.; Vallés, P. Hsp70/nitric oxide relationship in apoptotic modulation during obstructive nephropathy. Cell Stress Chaperones, 2008, 13(4), 413-20.
121. Zhou, M.S.; Schuman, I.H.; Jaimes, E.A.; Raij, L. Renoprotection by statins is linked to a decrease in renal oxidative stress, TGF-beta, and fibronectin with concomitant increase in nitric oxide bioavailability. Am. J. Physiol. Renal Physiol., 2008, 295(1), F53-9.
122. Zager, R.A.; Johnson, A. Renal cortical cholesterol accumulation is an integral component of the systemic stress response. Kidney Int, 2001, 60(6), 2299-310.
123. Parra, G.; Quiroz, Y.; Salazar, J.; Bravo, Y.; Pons, H.; Chavez, M.; Johnson, R.J.; Rodriguez-Iturbe, B. Experimental induction of salt- sensitive hypertension is associated with lymphocyte proliferative response to HSP70. Kidney Int. Suppl., 2008, (111), S55-9.
124. Nakada, J.; Matsura, T.; Okazaki, N.; Nishida, T.; Togawa, A.; Minami, Y.; Inagaki, Y.; Ito, H.; Yamada, K.; Ishibe, Y. Oral administration of geranylgeranylacetone improves survival rate in a rat endotoxin shock model: administration timing and heat shock protein 70 induction. Shock, 2005, 24(5), 482-7.
125. Bravo, J.; Quiroz, Y.; Pons, H.; Parra, G.; Herrera-Acosta, J.; Johnson, R.J.; Rodríguez-Iturbe, B. Vimentin and heat shock protein expression are induced in the kidney by angiotensin and by nitric oxide inhibition. Kidney Int. Suppl., 2003, (86), S46-51.
126. Yang, R.C.; Wang, C.I.; Chen, H.W.; Chou, F.P.; Lue, S.I.; Hwang, K.P. Heat shock treatment decreases the mortality of sepsis in rats. Kaohsiung J. Med. Sci., 1998, 14(11), 664-672.
127. de Cavanagh, E.M.; Inserra, F.; Ferder, M.; Ferder, L. From mitochondria to disease: role of the renin-angiotensin system. Am. J. Nephrol., 2007, 27(6), 545-553.
128. Silvagno, F.; De Vivo, E.; Attanasio, A.; Gallo, V.; Mazzucco, G.; Pescarmona, G. Mitochondrial localization of vitamin D receptor in human platelets and differentiated megakaryocytes. PLoS One, 2010, 5(1), e8670.
129. Crivello, J.F. Oxidative stress limits vitamin D metabolism by bovine proximal tubule cells in vitro. Arch. Biochem. Biophys., 1988, 262(2), 471-480.
130. Ago, T.; Matsushima, S.; Kuroda, J.; Zablocki, D.; Kitazono, T.; Sadoshima, J. The NADPH oxidase Nox4 and aging in the heart. Aging (Albany NY), 2010, 2(12), 1012-1016.
131. Rinaldi Tosi, M.E.; Bocanegra, V.; Manucha, W.; Gil Lorenzo, A.; Vallés, P.G. The Nrf2-Keap1 cellular defense pathway and heat shock protein 70 (Hsp70) response. Role in protection against oxidative stress in early neonatal unilateral ureteral obstruction (UUO). Cell Stress Chaperones, 2011, 16(1), 57-68.
132. Abadir, P.M.; Foster, D.B.; Crow, M.; Cooke, C.A.; Rucker, J.J.; Jain, A.; Smith, B.J.; Burks, T.N.; Cohn, R.D.; Fedarko, N.S.; Carey, R.M.; O'Rourke, B.; Walston, J.D. Identification and characterization of a functional mitochondrial angiotensin system. Proc. Natl. Acad. Sci. USA, 2011, 108(36), 14849-14854.